Literature DB >> 25123133

Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness.

Sara Chiappalupi1, Francesca Riuzzi1, Stefania Fulle2, Rosario Donato1, Guglielmo Sorci3.   

Abstract

Rhabdomyosarcoma is a muscle-derived malignant tumor mainly affecting children. The most frequent variant, embryonal rhabdomyosarcoma (ERMS) is characterized by overexpression of the transcription factor, PAX7 which prevents ERMS cells from exiting the cell cycle and terminally differentiating. However, a role for PAX7 in the invasive properties of ERMS cells has not been investigated in detail thus far. Here we show that ectopic expression of receptor for advanced glycation end-products (RAGE) in human ERMS cells results in the activation of a RAGE/myogenin axis which downregulates PAX7 by transcriptional and post-translational mechanisms, as in normal myoblasts, and reduces metastasis formation. High PAX7 sustains migration and invasiveness in ERMS cells by upregulating EPHA3 and EFNA1 and downregulating NCAM1 thus decreasing the neural cell adhesion molecule (NCAM)/polysialylated-NCAM ratio. Microarray gene expression analysis shows that compared with the RAGE(-ve) TE671/WT cells and similarly to primary human myoblasts, TE671/RAGE cells show upregulation of genes involved in muscle differentiation and cell adhesion, and downregulation of cell migration related and major histocompatibility complex class I genes. Our data reveal a link between PAX7 and metastasis occurrence in ERMSs, and support a role for the RAGE/myogenin axis in metastasis suppression. Thus, low RAGE expression in ERMS primary tumors may be predictive of metastatic behavior.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25123133     DOI: 10.1093/carcin/bgu176

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

Review 1.  The EPH/Ephrin System in Bone and Soft Tissue Sarcomas' Pathogenesis and Therapy: New Advancements and a Literature Review.

Authors:  Argyris C Hadjimichael; Alexandros Pergaris; Angelos Kaspiris; Athanasios F Foukas; Stefania Kokkali; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

Review 2.  Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

Authors:  Xiaofei Yu; Chunqing Guo; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2015-06-17       Impact factor: 6.242

3.  PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.

Authors:  J A Hanna; M R Garcia; J C Go; D Finkelstein; K Kodali; V Pagala; X Wang; J Peng; M E Hatley
Journal:  Cell Death Dis       Date:  2016-06-09       Impact factor: 8.469

4.  PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype.

Authors:  Shunlei Duan; Guohong Yuan; Xiaomeng Liu; Ruotong Ren; Jingyi Li; Weizhou Zhang; Jun Wu; Xiuling Xu; Lina Fu; Ying Li; Jiping Yang; Weiqi Zhang; Ruijun Bai; Fei Yi; Keiichiro Suzuki; Hua Gao; Concepcion Rodriguez Esteban; Chuanbao Zhang; Juan Carlos Izpisua Belmonte; Zhiguo Chen; Xiaomin Wang; Tao Jiang; Jing Qu; Fuchou Tang; Guang-Hui Liu
Journal:  Nat Commun       Date:  2015-12-03       Impact factor: 14.919

5.  Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.

Authors:  Terra Vleeshouwer-Neumann; Michael Phelps; Theo K Bammler; James W MacDonald; Isaac Jenkins; Eleanor Y Chen
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

Review 6.  RAGE in the pathophysiology of skeletal muscle.

Authors:  Francesca Riuzzi; Guglielmo Sorci; Roberta Sagheddu; Sara Chiappalupi; Laura Salvadori; Rosario Donato
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-10-18       Impact factor: 12.910

7.  Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.

Authors:  Sara Chiappalupi; Guglielmo Sorci; Aleksandra Vukasinovic; Laura Salvadori; Roberta Sagheddu; Dario Coletti; Giorgia Renga; Luigina Romani; Rosario Donato; Francesca Riuzzi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-03-11       Impact factor: 12.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.